[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 930,345 ordinary shares under the second tranche of its buyback programme. Reported trade prices ranged between £360.90 and £367.00 with a reported volume-weighted average price of £363.4411. After settlement the company states its registered share capital is 8,970,871,750 ordinary shares, of which 3,880,205 are held as treasury, leaving 8,966,991,545 ordinary shares with voting rights. The announcement points shareholders to a full trade breakdown and notes the release does not constitute an offer for securities.

Positive

• Buyback executed and cancelled, demonstrating follow-through on the announced share repurchase programme
• Full post-settlement share capital and voting-rights figures provided, aiding regulatory transparency and shareholder calculations
• Trade price details and link to individual trade breakdown provided in line with Market Abuse Regulation disclosure requirements

Negative

• Transaction size is immaterial relative to total issued shares, so it is unlikely to move per-share metrics or ownership materially
• No information on aggregate programme size or remaining authorization is provided in this notice

Insights

Corporate Governance Expert

TL;DR: A routine share cancellation that slightly reduces share count and updates the voting-rights figure for regulatory disclosure.

The company executed and cancelled 930,345 shares under its announced buyback tranche and published post-settlement share capital and voting-rights figures. Providing the precise share counts and a link to the individual trade breakdown meets disclosure requirements under the Market Abuse Regulation and UK transparency rules. The action maintains compliance and ensures shareholders can calculate notification thresholds. The size of the cancellation relative to total issued shares is extremely small, so governance control dynamics are not materially affected.

Equity Analyst

TL;DR: Technical share repurchase with immaterial impact on outstanding shares and likely no meaningful change to per-share metrics.

The transaction details include execution prices (high £367.00, low £360.90, VWAP £363.4411) which allow transparency on execution cost. The cancelled volume of 930,345 shares against roughly 8.97 billion registered shares represents a vanishingly small percentage, so EPS and ownership percentages will be essentially unchanged. The filing appropriately updates treasury holdings and voting-rights counts for investor reference.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	21 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

21 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 930,345 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	20 August 2025	20 August 2025	20 August 2025
Number of Shares purchased:	930,345	-	-
Highest price paid per Share (p):	367.0000	-	-
Lowest price paid per Share (p):	360.9000	-	-
Volume weighted average price paid per Share (p):	363.4411	-	-

Following the settlement of the above, the Company's registered share capital is 8,970,871,750 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,966,991,545 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/1566W_1-2025-8-20.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 21, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLN) cancel on 21 August 2025?

Haleon cancelled 930,345 ordinary shares under the second tranche of its buyback programme.

What were the execution prices for Haleon's share purchases?

Reported trade prices ranged from £360.90 to £367.00 with a VWAP of £363.4411.

What is Haleon's updated registered share capital and number of voting shares?

Registered share capital is 8,970,871,750 ordinary shares; 3,880,205 are treasury shares, leaving 8,966,991,545 ordinary shares with voting rights.

Where can I find the full breakdown of the individual trades?

The company provided a link to the individual trade breakdown: http://www.rns-pdf.londonstockexchange.com/rns/1566W_1-2025-8-20.pdf and the announcement is on www.haleon.com/investors.

Does this announcement constitute an offer for securities?

No. The announcement explicitly states it does not constitute an offer or solicitation of an offer for securities.